In the context of RET-mutant medullary thyroid carcinoma (MTC), it is recommended to use selpercatinib as a kinase inhibitor targeting various forms of rearranged during transfection (RET), including wildtype RET, multiple mutated RET isoforms, VEGFR1, and VEGFR3. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.